These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Intravenous Targeted Microbubbles Carrying Urokinase versus Urokinase Alone in Acute Peripheral Arterial Thrombosis in a Porcine Model. Nederhoed JH; Ebben HP; Slikkerveer J; Hoksbergen AWJ; Kamp O; Tangelder GJ; Wisselink W; Musters RJP; Yeung KK Ann Vasc Surg; 2017 Oct; 44():400-407. PubMed ID: 28546045 [TBL] [Abstract][Full Text] [Related]
23. Thrombolysis with prourokinase versus urokinase: an in vitro comparison. Fox D; Ouriel K; Green RM; Stoughton J; Riggs P; Cimino C J Vasc Surg; 1996 Apr; 23(4):657-66. PubMed ID: 8627903 [TBL] [Abstract][Full Text] [Related]
24. Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: long-term experience and comparison of original and current techniques. Valji K; Bookstein JJ; Roberts AC; Oglevie SB; Pittman C; O'Neill MP AJR Am J Roentgenol; 1995 Jun; 164(6):1495-500; discussion 1501-3. PubMed ID: 7754901 [TBL] [Abstract][Full Text] [Related]
25. Catheter-directed thrombolysis for deep venous thrombosis. Raju S; Fountain T; McPherson SH J Miss State Med Assoc; 1998 Mar; 39(3):81-4. PubMed ID: 9538591 [No Abstract] [Full Text] [Related]
26. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy. Semba CP; Bakal CW; Calis KA; Grubbs GE; Hunter DW; Matalon TA; Murphy TP; Stump DC; Thomas S; Warner DL J Vasc Interv Radiol; 2000 Mar; 11(3):279-87. PubMed ID: 10735420 [No Abstract] [Full Text] [Related]
27. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220 [TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion. Shortell CK; Queiroz R; Johansson M; Waldman D; Illig KA; Ouriel K; Green RM J Vasc Surg; 2001 Nov; 34(5):854-9. PubMed ID: 11700486 [TBL] [Abstract][Full Text] [Related]
29. Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis. Schneider J; Friderichs E; Günzler WA; Flohé L Thromb Res; 1989 Oct; 56(1):59-65. PubMed ID: 2512686 [TBL] [Abstract][Full Text] [Related]
30. Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis. Badylak SF; Voytik SL; Henkin J; Burke SE; Sasahara AA; Simmons A Thromb Res; 1991 May; 62(3):115-26. PubMed ID: 1716378 [TBL] [Abstract][Full Text] [Related]
31. Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial. Mahler F; Schneider E; Hess H; J Endovasc Ther; 2001 Dec; 8(6):638-47. PubMed ID: 11797982 [TBL] [Abstract][Full Text] [Related]
32. Accelerated thrombolysis. In vitro evaluation of agents and methods of administration. Bookstein JJ; Saldinger E Invest Radiol; 1985 Oct; 20(7):731-5. PubMed ID: 2933363 [TBL] [Abstract][Full Text] [Related]
33. Ultrasound guidance to gain access for the "lyse and wait" technique. Mahon BR J Vasc Interv Radiol; 1999 Jun; 10(6):833. PubMed ID: 10392957 [No Abstract] [Full Text] [Related]
34. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis. Valji K; Bookstein JJ Radiology; 1993 Mar; 186(3):873-6. PubMed ID: 8430201 [TBL] [Abstract][Full Text] [Related]
37. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. Collen D; Stassen JM; Verstraete M J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615 [TBL] [Abstract][Full Text] [Related]
38. [Fatal endocarditis as a complication of intra-arterial lysis therapy: a case report]. Schellhammer F; Landwehr P; Schulz A; Lackner K Rofo; 1997 Jun; 166(6):561-3. PubMed ID: 9273013 [No Abstract] [Full Text] [Related]
39. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone--a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis. Duda SH; Tepe G; Luz O; Ouriel K; Dietz K; Hahn U; Pereira P; Marsalek P; Ziemer G; Erley CM; Claussen CD Radiology; 2001 Dec; 221(3):689-96. PubMed ID: 11719664 [TBL] [Abstract][Full Text] [Related]
40. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. Korninger C; Matsuo O; Suy R; Stassen JM; Collen D J Clin Invest; 1982 Mar; 69(3):573-80. PubMed ID: 7199539 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]